Posts Tagged ‘IPO’

Common Citation Document Launched By Trilateral Patent Offices

Thursday, November 17th, 2011

This posting came with a set of presentation slides which you can find at the end of the post.

The Industry Trilateral (of which IPO is a member) initially proposed a Common Citation Document (CCD).  In response, the Trilateral have launched an electronic capability which consolidates access to citation data from the Trilateral Offices combining a priority-based family of patent applications with the cited prior art for each family application.  It is possible to enter the database by means of application numbers or patent numbers and obtain a listing of the entire patent family filed in the Trilateral Patent Offices, as well as all of the other offices that send information to the European Patent Office database.  Together with each of these applications is included the citations cited against that application in that particular country, as well as its applicable status as X, Y, A, etc.  For certain offices such as the European Patent Office and others, the data includes “enhanced information”, including particular sections of the citation that are relevant and the particular claims against which those citations are relevant.  This is the typical information in the Search Reports provided under the PCT.  The USPTO and JPO are planning in the near future to include such “enhanced information” in their reporting of the citations to this CCD. 

  (more…)

Siemens v. Saint-Gobain – What’s Sauce For The Goose May Leave The Gander Unscathed

Tuesday, March 8th, 2011

Contributed by Jim Nelson, J.D., Ph.D. of Schwegman Lundberg & Woessner, P.A.

The Siemens Medical Solutions USA, Inc. v. Saint-Gobain Ceramics & Plastics, Inc., (a copy is available at the end of this post) case presents a fundamental issue and holding about equivalents in the face of a patent covering the product alleged to infringe another patent under the DOE.

The Court said that an equivalent of the claims at issue is present even though that equivalent was literally claimed in another patent. Of course that holding tracks the rule we all have learned: domination. You can patent an improvement of an earlier patented invention but your patent will be dominated by that earlier patent. Usually, this domination rule is considered in terms of literal infringement, not doctrine of equivalents.

In this situation, the defendant offered a clever retort to the domination rule. The defendant said that because of the relation among equivalents, obviousness, the later patented product, the plaintiff needed to show equivalents by a higher degree of proof, clear and convincing evidence, not preponderance of evidence. The defendant based its argument upon the theory backed by case quotes such as that from Judge Nies: a substitution in a patented invention cannot be both nonobvious (leading to a patent on the substitution) and insubstantial (leading to infringement under DOE).

The majority of the Court disagreed. They said that obviousness is not tantamount to equivalents.

(more…)

OUTSIDE OPINIONS ARE STILL KEY TO AVOIDING WILLFUL INFRINGEMENT

Thursday, November 5th, 2009

By A. J. Nelson

The October 29th IPO summary reports on the Senate version of the bill (attached below) regarding willful infringement:

SENATE BILL CODIFIES SEAGATE STANDARD FOR WILLFUL INFRINGEMENT AND IMPOSES ADDITIONAL LIMITATIONS ON FINDING WILLFULNESS — Section 4 of S. 515, the patent reform bill that was reported out of the Senate Judiciary Committee on April 2, 2009, at p. 30 amends 35 U.S.C. §284 on willful infringement. The section continues the statutory provision that allows a court to increase damages up to triple the normal amount for willful infringement and adds extensive language to define “willfulness.” The section incorporates the “objective recklessness” standard of the Federal Circuit’s 2007 Seagate opinion and prescribes requirements for notice of infringement. Other permitted grounds for willfulness include intentional copying with knowledge of the patent and a second infringement finding. Willfulness cannot not be found if there was an informed, good faith belief of patent invalidity, unenforceability or no infringement. Willfulness cannot be pleaded until after a finding of infringement. IPO POSITION: IPO believes that in light of the Federal Circuit’s 2007 opinion in the Seagate case, patent reform legislation should not include any provision on willful infringement.

The bill includes a provision that willfulness cannot be found (the report incorrectly reads “cannot not”) if there was an “informed good faith belief of patent invalidity. unenforceability or no infringement.” If passed in this form, the provision likely would put back in place the need (but not obligation) to have a competent opinion before launching a product. While touted as a codification of Seagate, this Senate bill is thus a change from the understanding many litigators attribute to Seagate. As currently interpreted by many litigators, Seagate eliminates the obligation and need to have a competent opinion before launching a product. If this bill passes, companies still will not be obligated to have such competent opinions before launching but will have an express need to obtain such opinions. The need is founded upon the provision that willfulness cannot be found if there was a good faith belief of patent invalidity, unenforceability or non-infringement. A clear demonstration of such a good faith belief would be a competent written opinion by outside counsel.

Of course, the IPO, aka The Patent Owners Organization, opposes because the somewhat vague recklessness guideline promulgated by the Court can be seen as permitting very little Due Diligence and FTO work before a product is launched. The business owner can say in that instance “I had no idea that patent was out there. I was not reckless because my technical researchers said I was okay. They know the art. That is my good faith belief. After all, my researchers are at the forefront of this business.”

Many in the business of litigation currently subscribe to the allegedly smart view that the approach of little or no FTO work and no prior formal opinions preserves as much flexibility as possible for patent infringement litigation and does not commit to positions before litigation occurs. Is it smart business, however, to spend thousands or millions of dollars on development of a product without knowing whether or not a U.S. patent may stop sales cold in their tracks?

s.515.pdf

Director Kappos Speaks Out On The State Of The Patent Office

Thursday, September 17th, 2009

On September 15, 2009, Director David Kappos spoke at the National IPO Meeting in Chicago. (A link to the text is found below). I got calls almost immediately about various aspects of his comments. Like the blind folks trying to characterize an elephant, there are many “hints” in the remarks of changes to come. One caller said that the Director commented that an appeal process that is so complex that nearly half of the appeal briefs filed are rejected for formal defects is a failure by definition (my gloss). But note that he called for cutting the pendency of appeals to 3 months. The Director also seems to be willing to develop a “satellite examiner” program along the lines of the satellite attorney program that has worked well for our firm from the beginning (SLW now has six satellite shareholders). His comments about how he will not tolerate discrimination among technologies might relate to attacks on business method patents but could just as easily relate to the difficulties we practitioners encounter in getting biotech claims of reasonable scope. I will leave it to you to root other acorns of hope from the Director’s remarks. Perhaps this is the beginning of another chapter of change we can believe in!

Text of Director Kappos’ Speech